- Biosimilar legislation (7 years, 12 years, more, less?)
- Start-up funding up or steady, i.e. low.
- Genzyme saga – how long is the CEO going to stay.
- Is the acquisition trend by pharma RE: small biotechs holding or subsiding?
What are you thinking – other things to watch for.
Filed under: Uncategorized
A Biotech Entrepreneur's Musings 
Didn’t take long for #3 to happen: pay package, bad performance of the com here (http://www.fiercebiotech.com/story/biogen-ceo-calls-it-quits-after-7-turbulent-years/2010-01-05?utm_medium=nl&utm_source=internal) and here (http://www.masshightech.com/stories/2010/01/04/daily16-Biogen-CEO-Mullen-to-retire.html)